for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cansino Biologics Inc

6185.HK

現在値

222.20HKD

変化

-18.80(-7.80%)

出来高

2,057,484

本日のレンジ

215.00

 - 

240.20

52週レンジ

30.55

 - 

285.80

∙ 約20分前の相場を表示しています。

適時開示

Cansino Biologics' Shanghai Star Market IPO 4,547.87 Times Oversubscribed

Aug 2 (Reuters) - Cansino Biologics Inc :SAYS ITS SHANGHAI STAR MARKET IPO 4,547.87 TIMES OVERSUBSCRIBED.

Cansino Biologics To Issue 24.8 Mln A Shares At RMB209.71 Per A Share

July 30 (Reuters) - Cansino Biologics Inc <6185.HK>::TO ISSUE 24.8 MILLION A SHARES AT ISSUE PRICE OF RMB209.71 PER A SHARE.

CanSino Biologics Aims To Raise Up To 5.2 Bln Yuan In Shanghai IPO

July 29 (Reuters) - CANSINO BIOLOGICS INC <6185.HK>:SAYS IT AIMS TO RAISE UP TO 5.2 BILLION YUAN ($743.06 million) IN INITIAL SHANGHAI SHARE OFFERING.CANSINO BIOLOGICS SAYS TO SELL 24.8 MILLION A-SHARES AT 209.71 YUAN PER SHARE IN SHANGHAI IPO.

Cansino Biologics Says Recombinant Novel Coronavirus Vaccine Got Military Specially-Needed Drug Approval

June 29 (Reuters) - Cansino Biologics Inc <6185.HK>::RECOMBINANT NOVEL CORONAVIRUS VACCINE GOT MILITARY SPECIALLY-NEEDED DRUG APPROVAL WITH A VALID PERIOD FOR 1 YEAR.APPROVAL RECEIVED FROM HEALTH BUREAU OF LOGISTICS SUPPORT DEPARTMENT OF CENTRAL MILITARY COMMISSION ON JUNE 25.

Cansino Biologics Got Clinical Trial Application Approval For Recombinant Novel Coronavirus Vaccine

May 18 (Reuters) - Cansino Biologics Inc <6185.HK>::GOT CLINICAL TRIAL APPLICATION APPROVAL FOR RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) FROM HEALTH CANADA.

Canadian clinical trials to test CanSino Biologics Covid-19 vaccine candidate

May 16 (Reuters) - :FIRST CANADIAN CLINICAL TRIALS WILL TEST COVID-19 VACCINE CANDIDATE DEVELOPED BY CHINA-BASED CANSINO BIOLOGICS - CANADIAN GOV'T SPOKESPERSONS.

Cansino Biologics Says Application For Proposed Issue Of A Shares Of Co Approved

May 4 (Reuters) - Cansino Biologics Inc <6185.HK>::CANSINO BIOLOGICS INC- APPLICATION FOR PROPOSED ISSUE OF A SHARES OF CO APPROVED BY LISTING COMMITTEE FOR SCI-TECH INNOVATION BOARD.

Cansino Biologics Says All Companies Owned By LAV Entities To Dispose Of 4.108% Of Total Issued H Shares Of Co

April 7 (Reuters) - Cansino Biologics Inc <6185.HK>::INFORMED BY LAV MANAGEMENT THAT ALL CO'S OWNED BY LAV ENTITIES TO DISPOSE OF 4.108% OF TOTAL ISSUED H SHARES OF CO.AFTER DISPOSAL, LAV ENTITIES WILL TOGETHER HOLD ABOUT 15.516% OF TOTAL ISSUED H SHARES OF CO.

Cansino Biologics Says Recombinant Novel Coronavirus Disease Vaccine Approved For Trial

March 18 (Reuters) - Cansino Biologics Inc <6185.HK>::RECOMBINANT NOVEL CORONAVIRUS DISEASE VACCINE (ADENOVIRUS TYPE 5 VECTOR) APPROVED FOR CLINICAL TRIAL.

Cansino Biologics Says Co & Institute Of Biotechnology, Academy Of Military Medical Sciences Jointly Developing Recombinant Novel Coronavirus Vaccine

March 17 (Reuters) - Cansino Biologics Inc <6185.HK>::CO & INSTITUTE OF BIOTECHNOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES JOINTLY DEVELOPING RECOMBINANT NOVEL CORONAVIRUS VACCINE.JOINT DEVELOPERS SUBMITTED PRE-INVESTIGATIONAL NEW DRUG REVIEW APPLICATION FOR AD5-NCOV TO REGULATORY AUTHORITIES.INITIATED PREPARATION FOR CLINICAL TRIALS AND PRE-SCREENING OF VOLUNTEERS.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up